Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU (Rheumatology, Dermatology, Internal Medicine, Pneumology, Gastroenterology, Neurology).

NCT04513561 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT04513561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04513561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU (Rheumatology, Dermatology, Internal Medicine, Pneumology, Gastroenterology, Neurology).
Lead sponsor
University Hospital, Lille
Phase
Observational
Overall status
Completed
Start date
July 21, 2020
Completion date
August 27, 2020
Enrollment
921 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, inflammatory disease